

# **Navana Pharmaceuticals Limited**

**Interim Financial Statements (Un-audited)**  
*For the Period from 01 July 2022 -31 December 2022*

**Navana Pharmaceuticals Limited**  
Statement of Financial Position (Un-audited)  
As at 31 December 2022

(Amount in BDT)

Particulars	Notes	As at	
		31-Dec-2022	30-Jun-2022
<b>Assets</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	3.00	3,708,051,685	3,421,837,366
Intangible Asset	3.01	660,000	770,000
Capital Work in Progress	4.00	199,027,819	403,007,534
Right-of-Use Asset	5.00	187,384,430	204,018,990
Investment in Marketable Securities (Fair Value)	6.00	169,427,247	159,028,097
<b>Total Non-Current Assets</b>		<b>4,264,551,181</b>	<b>4,188,661,986</b>
<b>Current Assets:</b>			
Inventories	7.00	1,134,199,016	1,009,145,823
Trade and Other Receivables	8.00	589,172,658	547,819,881
Advances, Deposits and Prepayments	9.00	1,851,955,753	1,204,469,458
Goods In Transit	10.00	261,902,280	67,575,600
Cash and Cash Equivalents	11.00	650,489,616	66,427,585
<b>Total Current Assets</b>		<b>4,487,719,322</b>	<b>2,895,438,346</b>
<b>Total Assets</b>		<b>8,752,270,503</b>	<b>7,084,100,333</b>
<b>Equity And Liabilities</b>			
<b>Equity:</b>			
Paid-up Share Capital	12.00	1,074,162,170	802,301,500
Share Premium	13.00	450,209,562	-
Revaluation Reserve	14.00	1,966,271,633	1,966,271,633
Capital Reserve		605,590,148	605,590,148
Unrealized Gain/ (Loss) Reserve	6.00	(76,189,889)	(95,356,927)
Retained Earnings		229,642,054	204,242,971
<b>Total Equity:</b>		<b>4,249,685,678</b>	<b>3,483,049,324</b>
<b>Liabilities</b>			
<b>Non-Current Liabilities:</b>			
Loan from Directors	15.00	30,000,000	30,000,000
Lease Liabilities	16.02	104,350,155	100,720,006
Long Term Loan	17.02	25,820,495	141,390,720
Deferred Tax Liability	18.00	46,927,303	42,362,502
<b>Total Non-Current Liabilities</b>		<b>207,097,953</b>	<b>314,473,228</b>
<b>Current Liabilities:</b>			
Short Term Loan	19.00	3,602,714,114	2,682,055,890
Lease Liabilities (Current Maturity)	16.01	24,691,658	29,254,646
Long Term Loan (Current Maturity)	17.01	5,845,498	28,125,222
Trade and Other Payables	20.00	544,077,764	547,142,023
Dividend Payable		118,157,839	-
<b>Total Current Liabilities</b>		<b>4,295,486,872</b>	<b>3,286,577,781</b>
<b>Total Liabilities</b>		<b>4,502,584,825</b>	<b>3,601,051,009</b>
<b>Total Equity and Liabilities</b>		<b>8,752,270,503</b>	<b>7,084,100,333</b>
<b>Net Asset Value (NAV) Per Share</b>	30.00	<b>39.56</b>	<b>43.41</b>

Annexed notes are integral part of these financial statement.

  
Chief Financial Officer

  
Company Secretary

  
Managing Director

  
Director

  
Director

**Navana Pharmaceuticals Limited**  
**Statement of Profit or Loss and Other Comprehensive Income (Un-audited)**  
**For the period from 01 July 2022 to 31 December 2022**

(Amount in BDT)

Particulars	Notes	Half Yearly		Second Quarter	
		July-Dec'2022	July-Dec'2021	Oct-Dec'2022	Oct-Dec'2021
<b>Net Sales</b>	21.00	2,731,985,726	2,437,458,065	1,395,860,103	1,232,261,592
Less: Cost of Good Sold	22.00	1,475,493,092	1,356,630,333	747,501,671	694,774,789
<b>Gross Profit</b>		<b>1,256,492,634</b>	<b>1,080,827,732</b>	<b>648,358,431</b>	<b>537,486,803</b>
<b>Less: Operating Expenses</b>					
Administrative Expenses	23.00	100,786,936	82,384,963	59,288,682	44,692,136
Selling & Marketing Expenses	24.00	616,649,993	614,865,227	332,820,480	328,509,489
Distribution Expenses	25.00	188,586,128	148,947,190	95,129,309	72,697,585
<b>Total Operating Expenses:</b>		<b>906,023,057</b>	<b>846,197,380</b>	<b>487,238,471</b>	<b>445,899,210</b>
<b>Operating Profit</b>		<b>350,469,578</b>	<b>234,630,352</b>	<b>161,119,961</b>	<b>91,587,593</b>
Less: Finance Expenses	26.00	142,607,229	95,052,933	77,309,339	42,273,407
Add: Other Income/(loss)	27.00	(15,041,693)	70,129,296	(3,675,944)	59,675,686
<b>Profit before WPPF &amp; Tax</b>		<b>192,820,655</b>	<b>209,706,715</b>	<b>80,134,678</b>	<b>108,989,872</b>
Contribution to WPPF		9,181,936	9,808,223	3,815,937	5,012,182
<b>Profit before tax</b>		<b>183,638,719</b>	<b>199,898,492</b>	<b>76,318,741</b>	<b>103,977,690</b>
<b>Less: Income Tax</b>		<b>40,081,797</b>	<b>76,062,807</b>	<b>5,392,244</b>	<b>41,516,859</b>
Current Tax	28.00	35,516,996	76,311,579	18,993,226	45,951,686
Deferred Tax Expense/(Income)		4,564,800	(248,773)	(13,600,983)	(4,434,828)
<b>Profit after Tax</b>		<b>143,556,922</b>	<b>123,835,685</b>	<b>70,926,497</b>	<b>62,460,831</b>
<b>Other Comprehensive Income</b>					
Unrealized Gain/(loss) on Marketable Security		19,167,038	17,238,872	7,460,356	17,238,872
<b>Total Comprehensive Income</b>		<b>162,723,960</b>	<b>141,074,557</b>	<b>78,386,853</b>	<b>79,699,703</b>
<b>Earnings Per Share (EPS)</b>	29.00	<b>1.57</b>	<b>1.54</b>	<b>0.77</b>	<b>0.78</b>

Annexed notes are integral part of these financial statement.

  
Chief Financial Officer

  
Company Secretary

  
Managing Director

  
Director

  
Director

**Navana Pharmaceuticals Limited**  
Statement of Changes in Equity (Un-audited)  
For the period from 01 July 2022 to 31 December 2022

Particulars	(Amount in BDT)							
	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain/(Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2022	802,301,500	-	-	1,966,271,633	605,590,148	(95,356,927)	204,242,971	3,483,049,324
Profit after Tax	-	-	-	-	-	-	143,556,922	143,556,922
Received from IPO Share Subscription	-	-	750,000,018	-	-	-	-	750,000,018
Allotment of Shares for IPO	271,860,670	478,139,348	(750,000,018)	-	-	-	-	(118,157,839)
11% Cash Dividend for YE 30 June 2022	-	-	-	-	-	-	(118,157,839)	(118,157,839)
Less: Adj with IPO Expense	-	(27,929,786)	-	-	-	19,167,038	-	(27,929,786)
Adj. to Unrealized Gain/(Loss) on FVOCI	-	-	-	-	-	(76,189,889)	-	19,167,038
<b>Balance as at 31 December 2022</b>	<b>1,074,162,170</b>	<b>450,209,562</b>	<b>-</b>	<b>1,966,271,633</b>	<b>605,590,148</b>	<b>(76,189,889)</b>	<b>229,642,054</b>	<b>4,249,685,678</b>

Particulars	(Amount in BDT)							
	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain/(Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2021	802,301,500	-	-	1,966,271,633	-	-	535,831,580	3,304,404,713
Profit after Tax during the period	-	-	-	-	-	-	274,001,539	274,001,539
Transfer to Capital Reserve	-	-	-	-	605,590,148	-	(605,590,148)	-
Unrealized Gain/(Loss) on Marketable Securities	-	-	-	-	-	(95,356,927)	-	(95,356,927)
<b>Balance as at 31 December 2021</b>	<b>802,301,500</b>	<b>-</b>	<b>-</b>	<b>1,966,271,633</b>	<b>605,590,148</b>	<b>(95,356,927)</b>	<b>204,242,971</b>	<b>3,483,049,324</b>

  
Chief Financial Officer

  
Company Secretary

  
Managing Director

  
Director

  
Director